Release date: 16 June 2004
Promoter – Financial Intermediary
Fresenius – The Health Care Group.Location
Description
The project concerns the promoter’s Research and Development expenditures in medical care and biotechnology (antibodies and cell therapy) and upgrading of existing manufacturing facilities for dialysis and products.
Objectives
The research activities aim at the innovation of high-quality products and new therapy approaches in line with the Bank’s Innovation 2010 Initiative. The promoter’s main production facilities in dialysis technology are located in Objective 2 areas for allocations from the EU Structural Fund. The project will result in creation of some new jobs while safeguarding existing employment.
Comments
Fabrication of medical equipment and pharmaceuticals.
Sector(s)
Proposed EIB finance (Approximate amount)
EUR 232m.
Total cost (Approximate amount)
Up to EUR 330m.
Environmental aspects
Compliance with EU environmental directives and national laws shall be ensured.
Procurement
Procurement regulations do not apply to this private industry project. The promoter carries out competitive enquiries among potential suppliers for goods and services, as is usual in the industry.
Status
Signed - 13/07/2005